US Patent

US10683499 — Compositions and methods for modulating TTR expression

Method of Use · Assigned to Ionis Pharmaceuticals Inc · Expires 2034-08-25 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions and methods for modulating TTR expression using oligomeric compounds with conjugate groups.

USPTO Abstract

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2378`	—	eplontersen-sodium

Patent Metadata

Patent number: US10683499
Jurisdiction: US
Classification: Method of Use
Expires: 2034-08-25
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Ionis Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.